T hromboembolism from unstable atherosclerotic lesions in the carotid bifurcation is a major extracranial cause of ischemic stroke. 1 Despite a large body of literature, cellular and molecular processes that regulate the stability of atherosclerotic lesions are still not fully elucidated. Discoveries of signature proteins for unstable carotid atheroma can therefore increase our understanding of the pathophysiology behind plaque instability and may lead to development of preventive strategies against cerebral as well as myocardial consequences of atherosclerosis.
allowed the design of prospective cross-sectional studies relating plaque phenotype to local protein expression, as well as longitudinal and follow-up studies. 9 Gene microarray technology has been used in hypothesis-independent exploration to identify molecular mediators of atheroma destabilization and global gene-expression signatures in biobanks of diseased tissue, providing important clues to the underlying pathology. [10] [11] [12] Such investigations are expected to reveal a fingerprint of the vulnerable plaque and could ultimately lead to identification of biomarkers with sufficient predictive power.
Here, we combined information from large-scale microarray profiling of unstable (symptomatic) and stable (asymptomatic) carotid lesions in the Biobank of Karolinska Endarterectomies (BiKE) with high-throughput immunohistochemistry (IHC) techniques using tissue microarrays (TMAs) [13] [14] [15] to discover new molecular targets implicated in plaque instability (Figure 1 ). TMAs are collections of multiple tissue cores placed in parallel in a single acceptor paraffin block, thereby enabling simultaneous and standardized analyses of many samples concurrently. 16, 17 The application of TMA technology in this type of vascular disease analyses places our study among the very few that have attempted the same. 18 By this approach, we demonstrated upregulation of genes involved in inflammation, lipid metabolism, cell proliferation, and coagulation in symptomatic compared with asymptomatic carotid plaques, as well as differential expression of several proteins. PCSK6, a proprotein convertase (PC) previously not associated with atherosclerosis, was shown to be highly upregulated in symptomatic plaques both at the mRNA and protein levels, and predominantly expressed by SMCs of the fibrous cap. Given the functional importance of this structure in lesion pathology, we characterized PCSK6 in relation to other members of the PC family, ECM components, and cytokines previously implicated in plaque stability.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Microarray Profiling of Symptomatic Versus Asymptomatic Carotid Plaques
Large-scale microarray profiling was performed for 127 carotid endarterectomies (40 asymptomatic/87 symptomatic), and genes most highly upregulated in symptomatic versus asymptomatic plaques were extracted (Table) . Pathway analysis revealed that a majority of these genes were implicated in processes already known to be dominant in unstable lesions: immune response (CD163, EDNRB, S100A9, CR1); cell proliferation, adhesion, and apoptosis (GLUL, TNC, LMNB1); Figure 1 . Study design. Carotid plaques (n=34) from asymptomatic and symptomatic patients were sectioned at 2 levels and 3 cores drilled from each level (A) to construct 2 tissue microarray (TMA) blocks with 204 cores in total (B). Based on symptomatic vs asymptomatic microarray comparisons generated for n=127 plaques (C), highly upregulated genes were chosen for the study (D; in red). Several genes already known to be associated with atherosclerosis were also included (D; in black). TMAs were stained by immunohistochemistry (IHC) with antibodies toward human proteins of interest, and tissue sections were scored (0, 1, 2, or 3) for semiquantitative grading of staining intensity (E). Significantly differentially expressed proteins were validated further by IHC on individual plaques (F). October 2013 and lipid metabolism (SMPDL3A, NPC1, PLD1, SCD). Genes associated with glucose transport and metabolism (SDC2, SLC2A3, CA12) were also prominently upregulated, as well as various proteases (LGMN, CTSZ, CTSB, PCSK6). One of the functional clusters contained genes involved in coagulation and homeostasis of iron and heme (LAMP2, HMOX1, HFE) normally induced in tissue response to hemorrhages. Furthermore, cytokines associated with inflammation, cellular proliferation, and angiogenesis (TGFBI, VEGFA) were also overexpressed in these comparisons.
Differential Expression of Proteins in Carotid Plaques From Symptomatic Versus Asymptomatic Patients
From the list of highly upregulated genes obtained by microarray comparisons between symptomatic and asymptomatic carotid lesions, candidates with relatively restricted tissue distribution in humans were chosen for further analysis (based on the Human Protein Atlas). This approach was taken to exclude ubiquitously expressed housekeeping genes, presumably involved in basic cellular functions, and thereby avoid investigating processes not specifically related to atherosclerosis. The selection was further supplemented by a number of genes previously associated with unstable atherosclerosis and expected to serve as controls, thereby combining unbiased with hypothesis-driven approach for the study. Blinded semiquantitative grading of IHC stainings of totally 204 endarterectomy tissue cores on TMA sections was thereafter performed for 21 selected proteins (Tables II and III in the online-only Data Supplement; Figure II in the online-only Data Supplement). By Cronbach reliability analysis, we estimated an intraclass-correlation coefficient >0.9, indicating excellent reliability of the scoring data (Table IV in the  online-only Data Supplement) . Several proteins exhibited significantly differential staining intensity between asymptomatic and symptomatic plaques (representative images shown in Figure 2A ): CD36 (mean difference=0.31±0.12; P=0.012) and DOCK7 (mean=0.31±0.11; P=0.0137) were upregulated in symptomatic plaques, whereas CD137 was downregulated (mean=−0.19±0.09; P=0.411; Figure 2B ). Interestingly, PCSK6 was identified as the most significantly increased protein expressed in tissue cores (n=168) from symptomatic patients when compared with those from asymptomatic patients (n=36 cores), mean differ-ence=0.44±0.11; P<0.0001.
Localization of Differentially Expressed Proteins in Carotid Plaques
Identified differentially expressed proteins (CD36, CD137, DOCK7, PCSK6) were localized in individual endarterectomies by IHC and costaining with antibodies against cell-specific markers ( Figure 3 ). We observed widespread immunoreactivity for CD36 and CD137 that especially colocalized with macrophage and T-lymphocyte markers (CD163 and CD4/CD8, respectively). In addition, CD36 was occasionally found to be expressed by von Willebrand factor positive endothelial cells in plaque microvessels. DOCK7 exhibited a scattered staining pattern, most often associated with disorganized regions near and within the necrotic core, but could not be definitively colocalized with any of the cellular markers used. PCSK6 was the only protein that colocalized with smooth muscle α-actin positive (αSMA+) cells. A strong and Figure 2 . CD36, CD137, DOCK7, and PCSK6 are differentially expressed in asymptomatic vs symptomatic carotid plaques. Representative images of immunohistochemistry stainings on tissue microarrays are shown for the proteins identified as significantly differentially expressed between asymptomatic and symptomatic lesions (A). Graphs show quantification of staining intensity of all plaque cores with upregulation of CD36, DOCK7, and PCSK6 in symptomatic lesions, whereas CD137 was downregulated (B; mean with SD). Au indicates arbitrary units. consistent staining for PCSK6 was observed both intracellularly and in the ECM surrounding αSMA+ cells in the fibrous cap adjacent to the necrotic core. In addition, areas rich with CD163, CD4, and CD8+ inflammatory cells displayed some PCSK6 immunoreactivity, and the staining was also found adjacent to von Willebrand factor positive cells but without any obvious overlap with these markers.
Expression of PCs in Carotid Atherosclerosis
Because PCs have previously been implicated in human atherosclerosis, 19 we investigated the expression of this protease family in our biobank. Microarray analysis of RNA extracted from 127 human carotid plaques showed a significant downregulation of Furin and PCSK5, whereas PCSK6 and PCSK7 were upregulated ( Figure 4A ) in comparison with control iliac arteries (PCSK6 mean difference=1.82, P<0.0001; PCSK7 mean=0.51, P<0.01). Levels of PCSK2 and PCSK9 were increased; however, not significantly. Also, moderate-tostrong positive correlations were seen between the expression of PCSK6 and other PCs (except Furin and PCSK5) from the gene-array analyses ( Figure 4B ).
The human PCSK6 gene is transcribed into 10 mRNA isoforms and subsequently translated in the form of cytosolic, peripheral membrane, as well as secreted proteins (www.uniprot.org). Although all PCSK6 isoforms were upregulated in plaques compared with control tissues ( Figure 4C ), only the form coding for the secreted protein product displayed a significant upregulation in lesions from symptomatic compared with asymptomatic patients, as detected by the Affymetrix probe 207414_s_at (mean dif-ference=0.54; P<0.01; Figure 4D ). Microarray results were corroborated by quantitative real-time polymerase chain reaction analysis of mRNA coding for the secreted PCSK6 isoform in carotid plaques (n=233), showing a total increase of 19.21-fold, P<0.0001 in plaques versus controls ( Figure 4E ) and 8.21-fold, P<0.01 increase in symptomatic plaques versus asymptomatic plaques ( Figure 4F ). In further support of the association between PCSK6 and plaque instability, correlation of clinical variables to PCSK6 expression revealed a significant upregulation in lesions retrieved within 1 month after symptoms compared with lesions retrieved later as well as those retrieved from patients with previous myocardial infarction ( Figure III in the online-only Data Supplement). No significant correlations were found between PCSK6 mRNA levels and patients' age, sex, symptoms, comorbidities, cholesterol levels, or medication (including statins; Table V in the online-only Data Supplement). Strikingly, PCSK6 is the only PC studied here that exhibited further elevation at the mRNA level in symptomatic lesions in our biobank of carotid endarterectomies. 
PCSK6 mRNA Expression Positively Correlates With Markers of Carotid Plaque Instability and Inflammation
To assess the levels of PCSK6 in comparison with cellular and molecular processes previously suggested to be associated with unstable atherosclerosis, we performed correlation analyses between mRNA expression values from the microarrays for secreted PCSK6 and genes selected as specific markers of cells and processes previously described in atherosclerosis (Table VI in the online-only Data Supplement). Strong uniformly positive correlations were noted with markers of macrophages (CD163, CD40, RANK), and fair-tomoderate correlations were noted with T-lymphocytes (CD3, CD4, CD8), except with FoxP3 considered to be a marker of regulatory T-cells. PCSK6 mRNA levels were also positively correlated with typical markers of inflammation and apoptosis (interleukin-1β, nuclear factor-κB, tumor necrosis factor-α [TNFα], caspase). The correlations with mRNAs coding for proteins involved in matrix degradation, such as matrix metalloproteinase 9 (MMP9), TIMP1, ADAM9, and Heparanase, were strong and significantly positive. However, it was noted that PCSK6 levels selectively related to many, but not all, markers from this category as correlations to MMP2, MMP25, and ADAMs were inverse. Correlations with the most abundant proteins building the ECM in the plaques, such as collagen and laminin, were also disparate. Several growth factors and cytokines, both those exerting proinflammatory and anti-inflammatory effects (platelet-derived growth factor-β [PDGFβ], transforming growth factor-β1 [TGFβ1], TGFα, interleukin-10), were simultaneously upregulated with PCSK6. Surprisingly, correlations with all 5 SMC markers were moderate but significantly negative.
PCSK6 Protein Is Strongly Expressed by αSMA+ Cells in the Fibrous Cap
To test some of the PCSK6 correlations seen at the mRNA level and previous protein localization data, we costained carotid plaques and normal arteries for the localization of αSMA and PCSK6 ( Figure 5A ). Despite inverse correlations of gene expression with SMC markers in carotid plaques, IHC confirmed our initial protein localization results and demonstrated strong intracellular and extracellular staining for PCSK6 in scattered, spindle-shaped αSMA+ cells in the fibrous cap adjacent to the necrotic core ( Figure 5A , last row; Figure 5B , middle and left, arrowheads). Colocalization between αSMA and PCSK6 on the cellular level was confirmed by double immunofluorescence staining ( Figure 5C ). In contrast, PCSK6 expression was absent in αSMA+ cells in subintimal regions underneath the plaque, with remains of the vessel wall media present ( Figure 5B , most right panel, arrowheads). In normal radial arteries and in a normal carotid artery, PCSK6 exhibited a different expression pattern with predominant staining in the ECM surrounding SMCs in the media ( Figure 5A , top and middle rows). To investigate PCSK6 expression in SMCs in more detail, we examined human carotid SMCs cultured in serum on fibronectin. Under Figure 4 . PCSK6 is the most significantly upregulated proprotein convertase (PC) in symptomatic carotid plaques. Analyses of n=127 microarray profiles between carotid plaques (CP) and normal controls (iliac arteries [IA]) show significant downregulation of Furin and PCSK5 in plaque tissue, upregulation of PCSK6 and PCSK7, whereas PCSK9 and PCSK2 did not exhibit significant variation in expression (A). Positive correlation was found between expression of PCSK6 and PCSK9, PCSK2 and PCSK7, whereas negative was observed with PCSK5 (B). Several PCSK6 isoforms recognized by different Affymetrix probes were significantly upregulated in plaques compared with controls, but most highly the isoform coding for secreted protein (C). This isoform was the only one with significantly higher expression in comparison between symptomatic (s) and asymptomatic (as) plaques (D). Results were confirmed by quantitative real-time polymerase chain reaction (qRT-PCR) analyses for expression of secreted PCSK6 isoform in a separate cohort of n=233 carotid plaques (E and F). Micorarray data expressed as log2 value and qRT-PCR data as fold change compared with control. Data in A, C, and D show mean with SD, whereas median with interquartile range is depicted in E and F. ER indicates endoplasmatic reticulum.
these in vitro conditions, SMCs reside in a proliferative, synthetic phenotype. 20, 21 PCSK6 protein was distributed diffusely in the cytoplasm of SMCs in vitro and at peripheral cell extensions in proximity to the plasma membrane, overlapping with cortical actin ( Figure 5D ).
PCSK6 Colocalizes With Matrix Degradation-Related Proteins in Carotid Plaques
Because strong positive correlations were seen at the mRNA level between PCSK6 expression and several molecules associated with matrix remodeling, we investigated the distribution of these proteins in normal and diseased carotid artery tissue ( Figure 6 ). In normal carotid artery, IHC stainings for PCSK6 and MMP9 did not overlap; PCSK6 was found in the media, whereas MMP9 localized to adventitial regions. In contrast, these 2 proteins colocalized to a high extent in carotid plaques, both in the fibrous cap and adjacent to the necrotic core. PCSK6 colocalized with Heparanase both in the media of normal carotid artery and in αSMA+ cells in the fibrous cap of carotid plaques. At the subcellular level, PCSK6 was frequently observed toward the cell periphery, whereas Heparanase demonstrated a prominent cytoplasmic signal. In addition, a widespread overlap of PCSK6 with heparan sulfate, fibronectin, and collagen types I/IV was observed in both normal arteries and carotid plaques ( Figure IV in the onlineonly Data Supplement).
Expression of PCSK6 in SMCs Is Regulated by Cytokines
The association between plaque inflammation and PCSK6 expression by SMCs as indicated from correlation analyses of microarrays was examined in vitro ( Figure 7) . Human carotid SMCs were stimulated with platelet derived growth factor BB, TGFβ1 (individually and in combination), interferon-γ, and TNFα, and the expression of the secreted PCSK6 isoform was studied by quantitative real-time polymerase chain reaction. Rapid increase of PCSK6 mRNA levels compared with nonstimulated control cells was detected in response to platelet derived growth factor BB and TGFβ1 after 2 hours, reaching maximum after 4 hours (mean fold difference=9.13, P=0.03; mean=8.10, P=0.001, respectively), with subsequent gradual decline. A synergistic effect of platelet derived growth factor BB and TGFβ1 on PCSK6 expression was also seen (at 4 hours, mean=13.58; P=0.003). TNFα stimulation caused significant upregulation of PCSK6 already after 2 hours (mean=0.43; P=0.01). In contrast, the response profile of PCSK6 to interferon-γ stimulation was slower but showing constant induction for up to 24 hours (mean=7.46; P=0.018).
Discussion
Detailed investigations of plaques obtained from patients with symptomatic atherosclerosis are expected to provide expression maps of key molecules in plaque instability that may become valuable as future biomarkers for risk prediction. 22 In the present study, we evaluated a large-scale gene and protein expression profiling in a biobank of carotid endarterectomies as a pipeline for discovery of novel proteins differentially regulated in unstable carotid lesions. Genes associated with immune response, cell proliferation, lipid metabolism, as well as various proteases were upregulated in symptomatic lesions, and the same trend remained at the protein level. In particular, the secreted form of a PC, PCSK6, was found to be expressed significantly higher in carotid plaques compared with normal arteries, as well as in symptomatic compared with asymptomatic lesions both at the mRNA and protein level. To our knowledge, this study is the first to systematically examine the expression profile of PCSK6 in a clinical cohort of this size, specifically comprising carotid lesions. PCSK6 protein was mainly localized to and around αSMA+ cells within the fibrous cap. Its expression was moderately to strongly positively correlated to markers of macrophages, lymphocytes, apoptosis, and matrix degradation, suggesting an association with plaque inflammation. In support of this assumption, PCSK6 expression was induced by cytokines in cultured SMCs in vitro.
Understanding complex, multifactorial diseases, such as atherosclerosis, relies on the identification of molecules and processes that shift the equilibrium from healthy to diseased and from silent to symptomatic state. Here, we examined the molecular properties of stable versus unstable atherosclerotic lesions by using an exploratory workflow that yielded several proteins of considerable interest for further studies. Analysis of microarray data by Gene Ontology pathways highlighted similar functional processes ongoing in symptomatic carotid plaques compared with asymptomatic ones as several previously performed studies 10,22-26 with emphasis on inflammation, lipid biosynthesis, iron deposition, angiogenesis, and proteolysis. Discrete differences in levels of gene expression between these 2 disease states were also observed, indicating an underlying principal resemblance. Transcriptomic profiles presented here are founded on 127 carotid plaques in total, which is the largest study of this kind worldwide, intended to become the basis of a more extensive functional pathway and network analysis in the future.
The identification of the PC PCSK6 (also referred to as PACE4, SPC4) as the most significantly upregulated PC in symptomatic carotid plaques is a novel discovery, supported by microarray data as well as quantitative real-time polymerase chain reaction from an additional cohort of patients in our biobank. PCs are a family of multifaceted enzymes, whose role in atherogenesis is only recently gaining attention. 19, 27 Apart from PCSK9, which plays a critical part in the regulation of lipid homeostasis, 28 other PCs have been poorly characterized in cardiovascular diseases, especially in comparison with their well-documented functions in cancers. PCSK6 involvement in prostate cancer has been extensively studied, the protein itself proposed as a serum biomarker, 29 and even a selective PCSK6 inhibitor with antiproliferative effects on prostate cancer cells was recently developed. 30 It has been suggested that Furin and PCSK5 modulate inflammatory responses, 31 regulate membrane-type MMPs and integrin-processing in atherosclerosis, 32 whereas PCSK7 and PCSK2 have been detected in vascular SMCs and linked to myocardial infarction. 33, 34 Polymorphisms in the Furin and PCSK6 genes have also been associated with hypertension and cardiovascular risk, 35, 36 whereas single nucleotide polymorphisms in PCSK5 have been found to correlate with high-density lipoprotein levels. 37 In a recent study, 19 Furin was found to be widely upregulated in atherosclerotic lesions from the aorta, femoral, and carotid arteries, and so was PCSK6 although to a lesser extent, while the expression of other PCs was sporadically noted. Whereas Turpeinen et al 19 investigated the expression of PCs in a relatively small number of samples (n=26) from different vascular beds, access to the biobank of carotid endarterectomies permitted us to study these proteases in a large cohort (n=360 totally) specifically comprising advanced carotid lesions. Here, we found significant increase in expression of PCSK6 and PCSK7 in carotid plaques compared with control tissues, whereas the secreted form of PCSK6 was the only PC with significantly higher expression in symptomatic versus asymptomatic lesions. In agreement with previous reports, 19 no significant change in expression levels was observed for PCSK2 and PCSK9, strengthening the view that PCSK9 is involved in lipid metabolism rather than plaque vulnerability. Because of their structural similarities, both redundant and distinct functions of PCs have been reported 38 and, in this respect, the observed positive correlations between expressions of PCSK6 and several other PCs in carotid plaque gene-array analyses may be of interest.
Vascular SMCs possess inherent phenotypic plasticity to dedifferentiate into proliferative and synthetic cells that migrate into the intima to take part in lesion development. 39 In atherosclerotic plaques, these cells form the fibrous cap and contribute to plaque stability. 21 Here, intracellular and extracellular staining for PCSK6 was detected in αSMA+ elongated cells within the fibrous cap and adjacent to the necrotic core, whereas αSMA+ cells in subintimal regions with remaining vessel wall media were consistently negative for PCSK6 signal. A likely explanation for the observed negative correlations of PCSK6 with SMCs markers in the gene-arrays is an overrepresentation of PCSK6 negative SMCs in the remaining media of the endarterectomy specimens in comparison with scattered PCSK6 positive cells in the fibrous cap. Nevertheless, this staining pattern was consistent in all specimens, and we hypothesize that the induction of PCSK6 in SMCs may be involved in plaque remodeling. In favor of this notion, significantly higher levels of PCSK6 were observed in lesions from patients with recent symptomatic event compared with patients with more distant events, which may reflect the onset of repair mechanisms and plaque stabilization over time. 8, 10 Possibly of some relevance, a role for PCSK6 in vessel wall stability was recently suggested in aortic dissection. 40 PCSK6 has previously been linked to increased cancer cell motility and invasiveness by enhancing bioactivity of substrates such as MMP9 and Heparanase. 41, 42 Possibly, these properties may also modulate SMC function and influence plaque stability because PCSK6 expression strongly correlated with expression and localization of both enzymes. Previously, MMPs have been assigned a key role in plaque remodeling, 43 while we recently demonstrated increased expression of Heparanase in symptomatic carotid lesions. 18 Here, we also observed a colocalization between PCSK6 and heparan sulfate, which is in agreement with the unique features of this protease to anchor in the ECM by binding to heparan-sulfate proteoglycans. 41, 42 Because heparan-sulfate proteoglycans such as perlecan can take part in the control of SMC proliferation, 44, 45 the association between PCSK6, heparan sulfate, and Heparanase suggests that PCSK6 may be involved in the regulation of SMC growth in atherosclerosis.
Mitogenic, chemotactic, apoptotic, and survival factors influence SMC function in the lesion. PCSK6 may directly assist in processing and release of growth factors from extracellular depots or rearrangement of their gradients given the Figure 7 . Effect of cytokines on PCSK6 mRNA expression. Cultured human carotid smooth muscle cells were stimulated with platelet derived growth factor BB (PDGFBB), transforming growth factor-β1 (TGFβ1), interferon-γ (IFNγ), and tumor necrosis factor-α (TNFα), and alterations in secreted PCSK6 mRNA levels after 2, 4, 8, and 24 hours were examined by quantitative real-time polymerase chain reaction (qRT-PCR). Significant induction of PCSK6 mRNA was seen already after 4 hours on stimulation with PDGFBB, TGFβ1, and in combination of these 2 factors, with subsequent decline. PCSK6 was moderately but rapidly stimulated by TNFα after 2 hours, whereas IFNγ treatment caused a milder and slower stimulatory effect on secreted PCSK6 mRNA levels up to 24 hours. Data expressed as average mean fold change with SEM of experiments, compared with nonstimulated controls.
positive correlations with several of them in the gene-arrays and the experimentally shown influence on PCSK6 mRNA levels. Immune cells secrete various proinflammatory mediators, including TNFα and interferon-γ, which were shown to induce PCSK6 in SMCs in vitro. Combined with the positive correlations between PCSK6 expression and inflammation markers from the gene-arrays, it is plausible that this gene is induced in plaque SMCs by the enhanced inflammatory activity associated with plaque instability. Inflammation is also intimately coupled to other features of the unstable plaque, such as SMC apoptosis, reduced synthesis and increased degradation of ECM, and production of tissue factor. Simultaneously, potent mitogenic and chemoattractant stimuli such as PDGF can promote SMC proliferation and plaque stabilization. 46 Considering the rapid influence of platelet derived growth factor BB and TGFβ1 on PCSK6 mRNA levels after stimulation in vitro, 47 this protein may have a function in SMC proliferation. The balance between proliferation and death of SMCs profoundly affects the status of the atherosclerotic plaque, 46 possibly involving PCSK6 as one of the regulators.
In validation of the used experimental platform, several proteins previously reported in association with atherosclerosis were rediscovered here as differentially expressed in symptomatic carotid plaques. Increased levels of CD36 and DOCK7, both assigned with important functions in atherosclerosis, were detected in TMAs. 48, 49 By contrast, protein levels of CD137, a TNF receptor in T-cells, were suppressed, thus opposing previous findings at the mRNA level. 50 However, little is known about the role of CD137 in advanced atherosclerosis, and it is plausible that the protein levels are downregulated immediately after plaque rupture because it has been suggested that rapid changes in the expression of genes and proteins can cause variations in plaque stability. 51 Of note, a tendency toward increased staining in symptomatic lesions was observed for most other proteins studied here, although not reaching significance levels in our semiquantitative analyses. This indicates some limitations of our study; however, we anticipate that by including more patients in TMAs and quantifying with a finer grading-scale, small changes in protein expression levels may also be detected. Additionally, classification of plaques macroscopically or microscopically after endarterectomy for morphological parameters of plaque instability could further refine detection of subtle alterations on protein levels.
Taken together, our biobank-based large-scale plaque profiling by gene-and tissue microarrays was established as a useful platform in mining for signature proteins of carotid plaque instability. The PC PCSK6 was identified as a novel protein overexpressed in symptomatic lesions and may be associated with key processes in plaque rupture such as inflammation, ECM remodeling, and dysregulation of SMC proliferation. However, it must be emphasized that descriptive expression analyses from clinical samples cannot prove a causal relationship between increased gene expression and disease state. 19 Hence, it is possible that induction of PCSK6 reflects healing reactions after plaque rupture rather than plaque instability. Further investigations are necessary to elucidate the function of PCSK6 in atherosclerosis pathobiology.
A novel approach was used to identify proteins differentially expressed in unstable carotid atherosclerosis with a combination of transcriptomic and tissue microarray profiling. We demonstrate that the proprotein convertase PCSK6, a protein previously not associated with atherosclerosis, is upregulated in smooth muscle cells of the fibrous cap in symptomatic carotid plaques. The observed association between PCSK6 expression, inflammation, and matrix remodeling, as well as the known capacity of this enzyme to modulate the function of cytokines and matrix degrading proteases, indicates potential involvement in plaque stability. The work provides a platform for further exploration of signature proteins in carotid plaque instability as well as a basis for investigations of the functional importance of PCSK6 in this process. In addition, the possible value of PCSK6 as a biomarker should be considered together with development of pharmacological strategies aimed to prevent clinical consequences of unstable atherosclerosis such as myocardial infarction and stroke.
Significance
